GlassScriptPhysician profile
Brian A Costell
NPI 1174563688
$468,921.05
in general payments reported to CMS, 2019-2025
96 companies · $61K in 2025
The $61K reported for 2025 was more than what 98% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $87K · 2021: $108K · 2022: $34K · 2023: $31K · 2024: $72K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $30K · Food and Beverage: $22K · Travel and Lodging: $20K · Consulting Fee: $10K · Honoraria: $2,920 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,368.75 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $29,930.00 |
| Food and Beverage | $21,626.26 |
| Travel and Lodging | $20,418.96 |
| Consulting Fee | $10,064.00 |
| Honoraria | $2,920.00 |
| Education | $211.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $103,831.66 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Lilly USA, LLC | $96,269.49 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Amgen INC. | $63,124.44 | 2019-2025 | Uplizna, Aimovig |
| Allergan, INC. | $55,147.12 | 2019-2022 | |
| Eisai INC. | $53,486.21 | 2019-2025 | |
| C2n Diagnostics, LLC | $20,218.35 | 2025 | Precivityad2 |
| Biohaven Pharmaceuticals, INC. | $18,458.77 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $16,690.07 | 2019-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $6,158.93 | 2020-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $4,921.10 | 2022 | |
| Biogen, INC. | $2,937.71 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Argenx US, INC. | $2,680.04 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $2,560.94 | 2019-2025 | |
| Ucb, INC. | $2,190.11 | 2019-2025 | Briviact, Zilbrysq, Nayzilam |
| Catalyst Pharmaceuticals, INC. | $1,721.88 | 2020-2024 |
Show all 93 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,648.03 | 2019-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $1,005.94 | 2019-2025 | Ultomiris, Soliris |
| Genzyme Corporation | $900.73 | 2019-2024 | |
| Pfizer INC. | $878.57 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $878.31 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Mdd US Operations, LLC | $735.10 | 2019-2025 | Apokyn, Apokyn |
| Genentech USA, INC. | $729.56 | 2019-2025 | Ocrevus, Evrysdi, Ocrevus Zunovo |
| Takeda Pharmaceuticals U.S.A., INC. | $658.78 | 2019-2025 | Hyqvia, Gammagard |
| Csl Behring | $593.25 | 2019-2025 | Hizentra |
| Merz Pharmaceuticals, LLC | $590.06 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Neurelis, INC. | $553.01 | 2020-2025 | Valtoco |
| Abbott Laboratories | $546.34 | 2020-2024 | Infinity, Eterna |
| Neurocrine Biosciences, INC. | $495.19 | 2021-2025 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $474.23 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $407.93 | 2023-2025 | Purified Cortrophin Gel |
| Acadia Pharmaceuticals INC | $357.97 | 2019-2025 | Nuplazid, Daybue |
| Mallinckrodt Hospital Products INC. | $354.03 | 2020-2024 | Acthar |
| Janssen Pharmaceuticals, INC | $350.28 | 2021-2023 | Ponvory |
| Scilex Pharmaceuticals INC. | $336.07 | 2021-2025 | Ztlido |
| Celgene Corporation | $334.08 | 2020-2024 | Zeposia |
| Octapharma USA, INC. | $331.10 | 2021-2024 | Panzyga |
| Alnylam Pharmaceuticals INC. | $322.27 | 2019-2025 | Onpattro |
| Sk Life Science, INC. | $321.42 | 2020-2025 | |
| Upsher-Smith Laboratories LLC | $294.56 | 2019-2023 | |
| Harmony Biosciences LLC | $278.41 | 2021-2023 | Wakix |
| Axsome Therapeutics, INC. | $250.19 | 2025 | Symbravo |
| Tanabe Pharma America, INC. | $249.56 | 2021-2025 | Radicava |
| Acorda Therapeutics, INC | $239.86 | 2019-2024 | Inbrija, Ampyra |
| Grifols USA, LLC | $234.11 | 2019-2025 | Gamunex-C |
| Sunovion Pharmaceuticals INC. | $233.27 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $232.37 | 2022-2023 | Trudhesa |
| Avanir Pharmaceuticals, INC. | $207.38 | 2019-2021 | |
| Janssen Biotech, INC. | $173.70 | 2025 | |
| Jazz Pharmaceuticals INC. | $152.68 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $148.78 | 2024-2025 | Rexulti |
| Alfasigma USA, INC. | $108.47 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $106.89 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $101.23 | 2020-2022 | |
| Kyowa Kirin, INC. | $100.07 | 2020-2024 | Nourianz |
| Astrazeneca Pharmaceuticals LP | $90.23 | 2022-2025 | Wainua |
| Tg Therapeutics, INC. | $88.22 | 2025 | |
| Akcea Therapeutics, INC. | $77.19 | 2019-2020 | |
| Medtronic, INC. | $75.29 | 2023-2024 | Merocel, Reveal Linq, Interstim |
| Ipsen Biopharmaceuticals, INC | $70.94 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $70.48 | 2021-2023 | Spritam |
| Boston Scientific Corporation | $69.30 | 2021-2024 | Watchman Flx |
| Bausch Health US, LLC | $61.97 | 2019 | |
| Sumitomo Pharma America, INC. | $59.12 | 2023 | Aptiom |
| Horizon Therapeutics Plc | $57.86 | 2022-2023 | Uplizna |
| Livanova USA, INC. | $57.80 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Vanda Pharmaceuticals INC. | $56.61 | 2024-2025 | Ponvory |
| Aquestive Therapeutics, INC. | $53.77 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $51.53 | 2019 | |
| Kvk-Tech, INC. | $45.82 | 2019 | |
| Corium, LLC | $44.90 | 2023 | Adlarity |
| Springworks Therapeutics, INC. | $42.01 | 2024-2025 | Gomekli |
| Assertio Therapeutics, INC. | $35.20 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $33.46 | 2019-2021 | |
| Life Molecular Imaging LTD | $33.38 | 2025 | Neuraceq |
| Insightec,INC | $33.33 | 2024 | Exablate |
| Indivior INC. | $32.10 | 2019 | |
| Avion Pharmaceuticals | $30.91 | 2022 | |
| Arbor Pharmaceuticals, INC. | $29.02 | 2020 | |
| Merz North America, INC. | $29.01 | 2019 | |
| Aucta Pharmaceuticals, INC. | $28.42 | 2025 | Motpoly Xr |
| Currax Pharmaceuticals LLC | $26.78 | 2020 | |
| Mylan Specialty L.P. | $23.86 | 2024 | Glatiramer Acetate |
| Xeris Pharmaceuticals, INC. | $21.67 | 2021 | |
| Eli Lilly and Company | $21.41 | 2020-2025 | Kisunla, Amyvid |
| Revance Therapeutics, INC. | $21.01 | 2025 | Daxxify |
| Inspire Medical Systems, INC. | $20.42 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $20.32 | 2019 | |
| Dynasplint Systems INC. | $20.24 | 2019-2023 | Dynasplint |
| Ultragenyx Pharmaceutical INC. | $20.17 | 2022 | |
| Averitas Pharma INC. | $16.04 | 2025 | Qutenza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.79 | 2024 | Caplyta |
| Greenwich Biosciences, INC. | $13.44 | 2021 | |
| Vertical Pharmaceuticals, LLC | $11.43 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$104,554.56 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Costell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.